Combination therapy for uncomplicated falciparum malaria in Ugandan children: A randomized trial

JAMA

Volumn 297, Issue 20, 2007, Pages 2210-2219

  Dorsey, Grant ^a,d   Staedke, Sarah ^b   Clark, Tamara D ^a   Njama Meya, Denise ^c   Nzarubara, Bridget ^c   Maiteki Sebuguzi, Catherine ^c   Dokomajilar, Christian ^a   Kamya, Moses R ^c   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; FANSIDAR; ANTIMALARIAL AGENT; ARTEMETHER LUMEFANTRINE COMBINATION; ARTEMETHER-LUMEFANTRINE COMBINATION; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PYRIMETHAMINE; SESQUITERPENE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MUSCLE WEAKNESS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEIZURE; SINGLE BLIND PROCEDURE; UGANDA; UNSPECIFIED SIDE EFFECT; URBAN POPULATION; VOMITING; ANIMAL; COMPARATIVE STUDY; DRUG COMBINATION; INFANT; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PARASITEMIA; PRESCHOOL CHILD; TREATMENT OUTCOME;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SESQUITERPENES; SINGLE-BLIND METHOD; SULFADOXINE; TREATMENT OUTCOME; UGANDA; URBAN POPULATION;

EID: 34249699738     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.20.2210     Document Type: Article

References (21)

1. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004;71(suppl):1-15.
2. Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet. 2004;363:237-240.
3. Kremsner PG, Krishna S. Antimalarial combinations. Lancet. 2004;364:285-294.
4. World Health Organization. WHO Guidelines for the Treatment of Malaria. Geneva, Switzerland:WHO; 2006. Technical document WHO/HTM/MAL/2006.1108.
5. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 2002;360:2031-2038.
6. Rwagacondo CE, Niyitegeka F, Sarushi J, et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg. 2003;68:743-747.
7. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet. 2004;364:1950-1957.
8. Yeka A, Banek K, Bakyaita N, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med. 2005;2:e190.
9. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine - artesunate, and artemether- lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474-1480.
10. Davis JC, Clark TD, Kemble SK, et al. Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. Malar J. 2006;5:18.
11. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: WHO; 2003. Technical document WHO/RBM/HTM/2003.50.
12. World Health Organization. Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004. Geneva, Switzerland: WHO; 2005. Technical document WHO/HTM/MAL/2005.1103.
13. Greenhouse B, Myrick A, Dokomajilar C, et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg. 2006;75:836-842.
14. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-2209.
15. Fanello CI, Karema C, van Doren W, Rwagacondo CE, D'Alessandro U. Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. Trop Med Int Health. 2006;11:589-596.
16. Karema C, Fanello CI, Van Overmeir C, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin ((R))) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006;100:1105-1111.
17. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Burkina Faso: a randomized controlled trial. Lancet. 2007;369:491-498.
18. Giao PT, Binh TQ, Kager PA, et al. Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg. 2001;65:690-695.
19. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9-17.
20. Stepniewska K, Taylor WR, Mayxay M, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother. 2004;48:4271-4280.
21. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002;18:458-464.